The effects of ranibizumab (Lucentis) on retinal function in isolated perfused vertebrate retina

British Journal of Ophthalmology

Volumn 93, Issue 10, 2009, Pages 1396-1400

  Luke M ^a,d   Januschowski, K ^b   Luke J ^a   Peters, S ^a   Wirtz, N ^a   Yoruk E ^b   Luke C ^c   Bartz Schmidt, K U ^b   Grisanti, S ^a   Szurman, P ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

A WAVE; ANIMAL TISSUE; ARTICLE; B WAVE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTRORETINOGRAM; NONHUMAN; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CATTLE; ELECTRORETINOGRAPHY; RETINA; TISSUE CULTURE TECHNIQUES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 70349972616     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.157511     Document Type: Article

References (20)

1. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870 (Pubitemid 44547437)
2. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85:425-430 (Pubitemid 47542265)
3. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943
4. Pieramici DJ, Avery RL. Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther 2006;6:1237-1245 (Pubitemid 44714149)
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444 (Pubitemid 44511558)
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431 (Pubitemid 44511557)
7. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-1469 (Pubitemid 350106676)
8. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
9. Lüke M, Weiergräber M, Brand C, et al. The isolated perfused bovine retina - A sensitive tool for pharmacological research on retinal function. Brain Res Brain Res Protoc 2005;16:27-36. (Pubitemid 41774068)
10. Sickel W. Respiratory and electrical responses to light stimulation in the retina of the frog. Science 1965;148:648-651
11. Hanawa I, Tateishi T. The effect of aspartate on the electroretinogram of the vertebrate retina. Experientia 1970;26:1311-1312
12. Lüke M, Lüke C, Hescheler J, et al. Effects of phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina. J Ocul Pharmacol Ther 2005;21:305-314 (Pubitemid 41192901)
13. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733 (Pubitemid 40270359)
14. Lüke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006;90:1178-1182 (Pubitemid 44351153)
15. Horwitz H, Fehrenbacher J, Novotny W, et al. Bevacizumab plus irnotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 (Pubitemid 38702844)
16. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623.e1.
17. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633.e1-4
18. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053
19. Fraser-Bell S, Kaines A, Hykin PG. Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 2008;19:185-189
20. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.